C4 Therapeutics, Inc.(CCCC)Earnings, Financials & Key RatiosC4 Therapeutics, Inc. (CCCC) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's cash and equivalents have declined to $61.3M as of 2026Q1, suggesting that a dilutive capital raise may be imminent to sustain its current clinical development programs.
C4 Therapeutics, Inc. (CCCC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
C4 Therapeutics, Inc. (CCCC) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.20vs $0.25+20.2% | $6Mvs $4M+40.4% |
| Q1 2026 | Feb 26, 2026 | $0.18vs $0.31+41.9% | $11Mvs $5M+104.2% |
| Q4 2025 | Nov 6, 2025 | $0.44vs $0.47+6.4% | $11Mvs $4M+150.7% |
| Q3 2025 | Aug 7, 2025 | $0.37vs $0.38+2.6% | $6Mvs $7M-5.0% |
Recent stock market news and headlines for C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
Key metrics vs top competitors for C4 Therapeutics, Inc. (CCCC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.39 | $363.61M | -3.46 | 1.02% | -292.08% | -44.44% | — | |
| $8.00 | $516.17M | -6.25 | -0.3% | -247.54% | -44.39% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $491.34 | $124.98B | 32.07 | 9.57% | 35.4% | 23.93% | — | |
| $17.23 | $2.22B | 8.32 | 20.38% | 99.97% | 64.48% | — |
C4 Therapeutics, Inc. (CCCC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
C4 Therapeutics, Inc. (CCCC) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 15, 2026·SEC
May 12, 2026·SEC
Apr 10, 2026·SEC
Get notified when CCCC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
C4 Therapeutics, Inc. (CCCC) stock FAQ — growth, dividends, profitability & financials explained
C4 Therapeutics, Inc. (CCCC) reported $34.9M in revenue for fiscal year 2025. This represents a 80% increase from $19.4M in 2018.
C4 Therapeutics, Inc. (CCCC) grew revenue by 1.0% over the past year. Growth has been modest.
C4 Therapeutics, Inc. (CCCC) reported a net loss of $103.8M for fiscal year 2025.
C4 Therapeutics, Inc. (CCCC) has a return on equity (ROE) of -44.4%. Negative ROE indicates the company is unprofitable.
C4 Therapeutics, Inc. (CCCC) had negative free cash flow of $96.0M in fiscal year 2025, likely due to heavy capital investments.
